Iovance Biotherapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -334.39 M

Iovance Biotherapeutics, Inc. Operating Cash Flow is USD -334.39 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -12.98% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Iovance Biotherapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -384.28 M, a 20.55% change year over year.
  • Iovance Biotherapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -318.77 M, a 33.18% change year over year.
  • Iovance Biotherapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -239.35 M, a 18.35% change year over year.
  • Iovance Biotherapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -202.23 M, a 3.66% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities